Please login to the form below

Not currently logged in
Email:
Password:

SMC approves Glivec for GIST

Glivec has been approved for use within NHS Scotland as adjuvant post-surgery therapy to delay the recurrence of GIST

The Scottish Medicines Consortium (SMC) has approved the use of Novartis' imatinib (Glivec/Gleevec) within NHS Scotland for use in the adjuvant treatment of adults who are at a high risk of recurrence following complete resection of Kit (CD117)-positive gastrointestinal stromal tumours (GIST).

The drug advice notes that imatinib, given for a period of one year, significantly improved the estimated one year recurrence-free survival compared with placebo and was associated with an increase of 16.4 months in median time to recurrence in patients at high risk of relapse following resection. The economic case was demonstrated for a one-year adjuvant treatment duration only.

The SMC's decision is in contrast to the National Institute for Health and Clinical Excellence's (NICE) decision to reject the drug for use in England and Wales in August.

NICE stated that although there is evidence that giving imatinib as adjuvant post-surgery therapy can delay the recurrence of GIST, there is a lack of evidence relating to the clinical effectiveness of imatinib, in particular whether adjuvant imatinib extends life expectancy, how long treatment should be continued and whether resistance to imatinib develops.

15th September 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...
Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...

Infographics